Finanzen von LTGO (LTGO)LTGOLTGO

In the context of the broader market, LTGO competes directly with industry leaders such as PAHC and AVLN. With a market capitalization of $1.45B, it holds a significant position in the sector. When comparing efficiency, LTGO's gross margin of N/A stands against PAHC's 31.73% and AVLN's N/A. Such benchmarking helps identify whether Latigo Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company shows a P/E ratio of -36.00 and a forward P/E of 0, suggesting it is not generating profits currently. Additionally, the price-to-sales ratio is 0, indicating no revenue generation, and the price-to-free cash flow ratio is -32.71, highlighting cash flow issues.